Genotypes May Influence When Patients With DMD Have Loss of Ambulation
WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
Future Considerations for Friedreich Ataxia
Comorbidities and Complications Associated With Friedreich Ataxia
Challenges Associated With Friedreich Ataxia
Impact of Friedreich Ataxia on Quality of Life
Clinical Utility of the Modified Friedreich Ataxia Rating Scale
Diagnosis of Friedreich Ataxia
Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia
Friedreich Ataxia: Looking Forward at the Treatment Landscape
Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Payer Coverage Considerations for New Treatments for Alzheimer Disease